Cargando…
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes
There is concern that people with rheumatic disease, often treated with immunosuppressive or immunomodulatory medication, may be at an increased risk of poor outcomes of novel coronavirus disease-2019 (COVID-19). However, hyperinflammation is a major cause of morbidity and mortality in COVID-19 and...
Autores principales: | Grainger, Rebecca, Machado, Pedro M., Robinson, Philip C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756169/ https://www.ncbi.nlm.nih.gov/pubmed/33468418 http://dx.doi.org/10.1016/j.berh.2020.101657 |
Ejemplares similares
-
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
por: Grainger, Rebecca, et al.
Publicado: (2022) -
Rheumatic disease and COVID-19: epidemiology and outcomes
por: Hyrich, Kimme L., et al.
Publicado: (2020) -
Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment
por: Kaye, Alan D., et al.
Publicado: (2021) -
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs
por: Georgiev, Tsvetoslav
Publicado: (2020) -
Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases
por: Boyadzhieva, Vladimira Vasileva, et al.
Publicado: (2020)